Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-12-2019 | Original Paper

Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia

Authors: G. Fond, M. Faugere, C. Faget-Agius, M. Cermolacce, R. Richieri, L. Boyer, C. Lançon

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 8/2019

Abstract

Hypovitaminosis D has been associated with, respectively, major depressive disorder, schizophrenia (SZ), and cognitive disorders in the general population, and with positive and negative symptoms and metabolic syndrome in schizophrenia. The objective was to determine the prevalence of hypovitaminosis D and associated factors in a non-selected multicentric sample of SZ subjects in day hospital. Hypovitaminosis D was defined by blood vitamin D level < 25 nM. Depressive symptoms were assessed by the Calgary Depression Rating Scale Score and Positive and Negative Syndrome Scale Score. Anxiety disorders and suicide risk were evaluated by the Structured Clinical Interview for Mental Disorders. Functioning was evaluated with the Functional Remission of General Schizophrenia Scale. Hypovitaminosis D has been found in 27.5% of the subjects. In multivariate analysis, hypovitaminosis D has been significantly associated with, respectively, higher suicide risk (aOR = 2.67 [1.31–5.46], p = 0.01), agoraphobia (aOR = 3.37 [1.66–6.85], p < 0.0001), antidepressant consumption (aOR = 2.52 [1.37–4.64], p < 0.001), negative symptoms (aOR = 1.04 [1.01–1.07], p = 0.04), decreased functioning (aOR = 0.97[0.95–0.99], p = 0.01), and increased leucocytosis (aOR = 1.17 [1.04–1.32], p = 0.01) independently of age and gender. No association with alcohol use disorder, metabolic syndrome, peripheral inflammation, insulin resistance, or thyroid disturbances has been found (all p > 0.05). Despite some slight abnormalities, no major cognitive impairment has been associated with hypovitaminosis D in the present sample (all p > 0.05 except for WAIS similarities score). Hypovitaminosis D is frequent and associated with suicide risk, agoraphobia and antidepressant consumption in schizophrenia, and more slightly with negative symptoms. Patients with agoraphobia, suicide risk and antidepressant consumption may, therefore, benefit in priority from vitamin D supplementation, given the benefit/risk profile of vitamin D. Further studies should evaluate the impact of vitamin D supplementation on clinical outcomes of SZ subjects.

Adamson J, Lally J, Gaughran F, Krivoy A, Allen L, Stubbs B (2017) Correlates of vitamin D in psychotic disorders: a comprehensive systematic review. Psychiatry Res 249:78–85. https://doi.org/10.1016/j.psychres.2016.12.052 CrossRefPubMed

Addington D, Addington J, Maticka-Tyndale E (1993) Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 39–44CrossRef

Akinlade KS, Olaniyan OA, Lasebikan VO, Rahamon SK (2017) Vitamin D levels in different severity groups of schizophrenia. Front Psychiatry 8:105. https://doi.org/10.3389/fpsyt.2017.00105 CrossRefPubMedPubMedCentral

Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23:469–480. https://doi.org/10.1111/j.1464-5491.2006.01858.x CrossRefPubMed

Andrianarisoa M, Boyer L, Godin O, Brunel L, Bulzacka E, Aouizerate B, Berna F, Capdevielle D, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Llorca PM, Mallet J, Misdrahi D, Rey R, Richieri R, Passerieux C, Schandrin A, Tronche AM, Urbach M, Vidailhet P, Schürhoff F, Fond G, Group FACE-SCZ (2017) Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort. Schizophr Res 185:173–181. https://doi.org/10.1016/j.schres.2016.12.021 CrossRefPubMed

Archontogeorgis K, Nena E, Papanas N, Rizzo M, Voulgaris A, Xanthoudaki M, Kouratzi M, Ragia G, Manolopoulos V, Zissimopoulos A, Froudarakis M, Steiropoulos P (2018) Metabolic syndrome and vitamin D Levels in patients with obstructive sleep apnea syndrome. Metab Syndr Relat Disord 16:190–196. https://doi.org/10.1089/met.2017.0181 CrossRefPubMed

Barbalho SM, Tofano RJ, de Campos AL, Rodrigues AS, Quesada K, Bechara MD, de Alvares Goulart R, Oshiiwa M (2018) Association between vitamin D status and metabolic syndrome risk factors. Diabetes Metab Syndr. https://doi.org/10.1016/j.dsx.2018.03.011 CrossRefPubMed

Belvederi Murri M, Respino M, Masotti M, Innamorati M, Mondelli V, Pariante C, Amore M (2013) Vitamin D and psychosis: mini meta-analysis. Schizophr Res 150:235–239. https://doi.org/10.1016/j.schres.2013.07.017 CrossRefPubMed

Belzeaux R, Annweiler C, Bertrand JA, Beauchet O, Pichet S, Jollant F, Turecki G, Richard-Devantoy S (2018) Association between hypovitaminosis D and cognitive inhibition impairment during major depression episode. J Affect Disord 225:302–305. https://doi.org/10.1016/j.jad.2017.08.047 CrossRefPubMed

10.

Belzeaux R, Boyer L, Ibrahim EC, Féron F, Leboyer M, Fond G (2015) Mood disorders are associated with a more severe hypovitaminosis D than schizophrenia. Psychiatry Res. https://doi.org/10.1016/j.psychres.2015.04.039 CrossRefPubMed

11.

Bender R, Lange S (2001) Adjusting for multiple testing—when and how? J Clin Epidemiol 54:343–349. https://doi.org/10.1016/S0895-4356(00)00314-0 CrossRefPubMed

12.

Boerman R, Cohen D, Schulte PFJ, Nugter A (2016) Prevalence of vitamin D deficiency in adult outpatients with bipolar disorder or schizophrenia. J Clin Psychopharmacol 36:588–592. https://doi.org/10.1097/JCP.0000000000000580 CrossRefPubMed

13.

Bogers JPAM, Bostoen T, Broekman TG (2016) Low levels of vitamin D poorly responsive to daylight exposure in patients with therapy-resistant schizophrenia. Nord J Psychiatry 70:262–266. https://doi.org/10.3109/08039488.2015.1086023 CrossRefPubMed

14.

Boyer L, Richieri R, Guedj E, Faget-Agius C, Loundou A, Llorca P-M, Auquier P, Lançon C (2013) Validation of a functional remission threshold for the Functional Remission of General Schizophrenia (FROGS) scale. Compr Psychiatry 54:1016–1022. https://doi.org/10.1016/j.comppsych.2013.04.008 CrossRefPubMed

15.

Cieslak K, Feingold J, Antonius D, Walsh-Messinger J, Dracxler R, Rosedale M, Aujero N, Keefe D, Goetz D, Goetz R, Malaspina D (2014) Low vitamin D levels predict clinical features of schizophrenia. Schizophr Res 159:543–545. https://doi.org/10.1016/j.schres.2014.08.031 CrossRefPubMedPubMedCentral

16.

Doğan Bulut S, Bulut S, Görkem Atalan D, Berkol T, Gürçay E, Türker T, Aydemir Ç (2016) The relationship between symptom severity and low vitamin D levels in patients with schizophrenia. PloS One 11:e0165284. https://doi.org/10.1371/journal.pone.0165284 CrossRefPubMedPubMedCentral

17.

Firth J, Carney R, Stubbs B, Teasdale SB, Vancampfort D, Ward PB, Berk M, Sarris J (2017) Nutritional deficiencies and clinical correlates in first-episode psychosis: a systematic review and meta-analysis. Schizophr Bull. https://doi.org/10.1093/schbul/sbx162 CrossRefPubMedPubMedCentral

18.

Fond G et al. (2018) Insufficient remission of depression in subjects with schizophrenia and comorbid major depressive disorder. Results from the FACE-SZ cohort. Br J Psychiatry

19.

Fond G, Guillaume S, Jaussent I, Beziat S, Macgregor A, Bernard P, Courtet P, Bailly D, Quantin X (2013) Prevalence and smoking behavior characteristics of nonselected smokers with childhood and/or adult self-reported ADHD symptoms in a smoking-cessation program: a cross-sectional study. J Atten Disord. https://doi.org/10.1177/1087054713497396 CrossRefPubMed

20.

Garbossa SG, Folli F (2017) Vitamin D, sub-inflammation and insulin resistance. A window on a potential role for the interaction between bone and glucose metabolism. Rev Endocr Metab Disord 18:243–258. https://doi.org/10.1007/s11154-017-9423-2 CrossRefPubMed

21.

Graham KA, Keefe RS, Lieberman JA, Calikoglu AS, Lansing KM, Perkins DO (2015) Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Interv Psychiatry 9:397–405. https://doi.org/10.1111/eip.12122 CrossRefPubMed

22.

Grundy SM (2005) Diagnosis and management of the metabolic syndrome: an american heart association/national heart, lung, and blood institute scientific statement. Circulation 112:2735–2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404 CrossRefPubMed

23.

Ju S-Y, Lee Y-J, Jeong S-N (2013) Serum 25-hydroxyvitamin D levels and the risk of depression: a systematic review and meta-analysis. J Nutr Health Aging 17:447–455. https://doi.org/10.1007/s12603-012-0418-0 CrossRefPubMed

24.

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276CrossRef

25.

Kim D (2017) The role of vitamin D in thyroid diseases. Int J Mol Sci. https://doi.org/10.3390/ijms18091949 CrossRefPubMedPubMedCentral

26.

Krivoy A, Onn R, Vilner Y, Hochman E, Weizman S, Paz A, Hess S, Sagy R, Kimhi-Nesher S, Kalter E, Friedman T, Friedman Z, Bormant G, Trommer S, Valevski A, Weizman A (2017) Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled clinical trial. EBioMedicine 26:138–145. https://doi.org/10.1016/j.ebiom.2017.11.027 CrossRefPubMedPubMedCentral

27.

Lerner PP, Sharony L, Miodownik C (2018) Association between mental disorders, cognitive disturbances and vitamin D serum level: current state. Clin Nutr ESPEN 23:89–102. https://doi.org/10.1016/j.clnesp.2017.11.011 CrossRefPubMed

28.

Llorca P-M, Lançon C, Lancrenon S, Bayle F-J, Caci H, Rouillon F, Gorwood P (2009) The “Functional Remission of General Schizophrenia” (FROGS) scale: development and validation of a new questionnaire. Schizophr Res 113:218–225. https://doi.org/10.1016/j.schres.2009.04.029 CrossRefPubMed

29.

Nerhus M, Berg AO, Kvitland LR, Dieset I, Hope S, Dahl SR, Weibell MA, Romm KL, Faerden A, Andreassen OA, Melle I (2016) Low vitamin D is associated with negative and depressive symptoms in psychotic disorders. Schizophr Res 178:44–49. https://doi.org/10.1016/j.schres.2016.08.024 CrossRefPubMed

30.

Park J-I, Yang J-C, Park W, Chung T, S.-K (2016) Is serum 25-hydroxyvitamin D associated with depressive symptoms and suicidal ideation in Korean adults? Int J Psychiatry Med 51:31–46. https://doi.org/10.1177/0091217415621042 CrossRefPubMed

31.

Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M (1993) Development of the alcohol use disorders identification test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol consumption-II. addict. Abingdon Engl 88:791–804

32.

Shivakumar V, Kalmady SV, Amaresha AC, Jose D, Narayanaswamy JC, Agarwal SM, Joseph B, Venkatasubramanian G, Ravi V, Keshavan MS, Gangadhar BN (2015) Serum vitamin D and hippocampal gray matter volume in schizophrenia. Psychiatry Res 233:175–179. https://doi.org/10.1016/j.pscychresns.2015.06.006 CrossRefPubMed

33.

Souberbielle J-C, Massart C, Brailly-Tabard S, Cavalier E, Chanson P (2016) Prevalence and determinants of vitamin D deficiency in healthy French adults: the VARIETE study. Endocrine 53:543–550. https://doi.org/10.1007/s12020-016-0960-3 CrossRefPubMed

34.

Tardelli VS, Lago MPP, do Silveira DX, da Fidalgo TM (2017) Vitamin D and alcohol: a review of the current literature. Psychiatry Res 248:83–86. https://doi.org/10.1016/j.psychres.2016.10.051 CrossRefPubMed

35.

Unité de surveillance et d’épidémiologie nutritionnelle (2007) Étude nationale nutrition santé ENNS,2006. Situation nutritionnelle en France en 2006 selon les indicateurs d’objectif et les repères du Programme national nutrition santé (PNNS). Institut de veille sanitaire,Université de Paris 13, Conservatoire national des arts et métiers, p 46

36.

Wang S, Wu Y, Zuo Z, Zhao Y, Wang K (2018) The effect of vitamin D supplementation on thyroid autoantibody levels in the treatment of autoimmune thyroiditis: a systematic review and a meta-analysis. Endocrine 59:499–505. https://doi.org/10.1007/s12020-018-1532-5 CrossRefPubMed

37.

Wysokiński A, Margulska A, Strzelecki D, Kłoszewska I (2014) Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nord J Psychiatry. https://doi.org/10.3109/08039488.2014.984755 CrossRefPubMed

38.

Yoo T, Choi W, Hong J-H, Lee J-Y, Kim J-M, Shin I-S, Yang SJ, Amminger P, Berk M, Yoon J-S, Kim S-W (2018) Association between vitamin D insufficiency and metabolic syndrome in patients with psychotic disorders. Psychiatry Investig 15:396–401. https://doi.org/10.30773/pi.2017.08.30 CrossRefPubMedPubMedCentral

39.

Yüksel RN, Altunsoy N, Tikir B, Cingi Külük M, Unal K, Goka S, Aydemir C, Goka E (2014) Correlation between total vitamin D levels and psychotic psychopathology in patients with schizophrenia: therapeutic implications for add-on vitamin D augmentation. Ther Adv Psychopharmacol 4:268–275. https://doi.org/10.1177/2045125314553612 CrossRefPubMedPubMedCentral

40.

Zhu D, Liu Y, Zhang A, Chu Z, Wu Q, Li H, Ge J, Dong Y, Zhu P (2015) High levels of vitamin D in relation to reduced risk of schizophrenia with elevated C-reactive protein. Psychiatry Res 228:565–570. https://doi.org/10.1016/j.psychres.2015.05.051 CrossRefPubMed

41.

Zhu W, Heil DP (2018) Associations of vitamin D status with markers of metabolic health: a community-based study in Shanghai, China. Diabetes Metab Syndr https://doi.org/10.1016/j.dsx.2018.04.010 CrossRefPubMed

Title: Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia
Authors: G. Fond
M. Faugere
C. Faget-Agius
M. Cermolacce
R. Richieri
L. Boyer
C. Lançon
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 8/2019
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-018-0932-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2019

The cognitive, affective motivational and clinical longitudinal determinants of apathy in schizophrenia

Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer’s disease from bioptic olfactory mucosa

Executive dysfunctions differentially predict amotivation in first-episode schizophrenia-spectrum disorder: a prospective 1-year follow-up study

Correction to: How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review

Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine

Specificity proteins 1 and 4 in peripheral blood mononuclear cells in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial